Lupus Genetics Studies (LFRR)
|ClinicalTrials.gov Identifier: NCT00071175|
Recruitment Status : Completed
First Posted : October 15, 2003
Last Update Posted : September 18, 2017
|Condition or disease|
|Systemic Lupus Erythematosus|
SLE is an often crippling and potentially fatal autoimmune disease that is nine times more prevalent in women than in men, and four times more likely to affect African American females than Caucasian females. It is suspected that a genetic predisposition along with environmental factors contribute to the clinical manifestation of SLE. The Lupus Genetics Studies consist of several familial SLE studies, including the Lupus Family Registry & Repository (LFRR, formerly known as the Lupus Multiplex Registry & Repository, or LMRR). The Lupus Studies enroll families of all ethnicities with one or more members diagnosed with systemic lupus to determine what genes contribute to the development of the disease.
Additionally, the Lupus Family Registry & Repository is the largest repository of its kind in North America. In addition to the research done on site, the Repository serves as a national resource for scientists interested in conducting research on SLE and families either simplex or multiplex for lupus. Data, serum samples, and DNA samples are available to researchers. By collecting families in which two or more living individuals have been diagnosed with SLE, the study is utilizing the genetic link between the affected family members to discover disease-associated genes.
Records will be requested from the patients' treating physicians to document various lupus symptoms and related problems. One-time blood samples will be collected from the patients as well as from certain family members and an unrelated volunteer. There is no cost to participate and the study pays for sample draws and shipping.
|Study Type :||Observational|
|Actual Enrollment :||3460 participants|
|Official Title:||Lupus Genetic Studies; Lupus Family Registry & Repository|
|Study Start Date :||October 1995|
|Primary Completion Date :||September 2012|
|Study Completion Date :||November 2013|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00071175
|United States, Oklahoma|
|Oklahoma Medical Research Foundation|
|Oklahoma City, Oklahoma, United States, 73104|
|Principal Investigator:||John B. Harley, MD, PhD||Member & Program Head, Arthritis and Immunology Research Program; Oklahoma Medical Research Foundation|